ReviewFrontiers in medicine2026
Impact of biologic and targeted synthetic therapies on bone health in immune-mediated inflammatory diseases: a narrative review.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteoporosis is a systemic skeletal disorder characterized by reduced bone mass, impaired microarchitecture, and increased fracture risk. Patients with immune-mediated inflammatory diseases (IMIDs) have a higher prevalence of osteoporosis owing to chronic inflammation, glucocorticoid use, and disease-specific factors. Pro-inflammatory cytokines such as TNF- Objective: This narrative review aims to evaluate the effects of biological disease-modifying anti-rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) on bone metabolism and fracture risk in adults with IMIDs. Methods: A comprehensive literature search was conducted in Ovid Medline, Embase, and the Cochrane Central Register of Controlled Trials from 2015 to August 2025, using MeSH and free-text terms. Reference lists of included studies were manually screened. Search strategies were validated by an expert librarian. Results: bDMARDs and tsDMARDs, including TNF- Conclusion: bDMARDs and tsDMARDs appear to preserve or modestly improve bone mass and positively influence bone turnover in IMIDs. However, increased BMD does not consistently translate into lower fracture risk, and current evidence is insufficient to draw definitive conclusions regarding the effect of bDMARDs and tsDMARDs on fracture risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.